mm2 Asia kept on 'buy' with strong earnings growth expected to continue

mm2 Asia kept on 'buy' with strong earnings growth expected to continue

By: 
Stanislaus Jude Chan
08/02/18, 03:34 pm

SINGAPORE (Feb 8): DBS Group Research is keeping its “buy” call on mm2 Asia with a marginally higher target price of 75 cents, from 73 cents previously.

This comes after the film producer and distributor saw its earnings surge 52% to $6.4 million for the 3Q ended December.

3Q18 revenue nearly trebled to $52.4 million on the back of newly-acquired cinemas in Malaysia and Singapore.

See: mm2 Asia reports 52% rise in 3Q earnings to $6.4 mil; issues $48 mil debt to finance cinema ops

“We continue to expect strong earnings CAGR of 28% for FY17-20F, underpinned by growth in productions, expansion into the China market, and contribution from UnUsUaL,” says analyst Ling Lee Keng in a Thursday report.

“The cinema arm, on the other hand, helps the group build a recurring income base. Having a strong presence in the entire value chain of content creation and distribution further cements mm2's status as the leader in the media/entertainment industry,” Ling adds.

While the recent cinema acquisitions boosted mm2’s 3Q revenue, Ling notes that it dragged down margins.

“3Q18 net margin eased to 12.3%, from 14.6% in 2Q18 and 23.3% in 3Q17, partly due to the increasing contribution from the cinema arm, which has lower margins,” Ling says. “We have lowered FY18F to FY19F earnings by 9-11%, after accounting for slightly lower revenue from the cinema segment and higher interest costs.”

Looking forward, Ling believes that mm2 could receive a boost from its expansion into North Asia, including China, Hong Kong, and Taiwan.

“Productions in these markets are expected to continue to form a bigger part of its revenue into FY2019,” says Ling. “We expect North Asia to contribute about 70% of production revenue from FY18F, up from 36% in FY16 and 56% in FY17.”

As at 3.26pm, shares of mm2 Asia are trading half a cent higher at 50 cents, implying an estimated price-to-earnings ratio of 22.7 times for FY18.

SGX stock falls 2% before midday break on news of potential injunction

SINGAPORE (May 22): Singapore Exchange (SGX) is facing a potential interim injunction on the India equity derivative products it intends to launch in June this year, but maintains that it nonetheless will continue to list the products as planned. To recap, SGX earlier announced its intention to launch three derivative products in June 2018 – SGX India futures, SGX India options and SGX India bank futures – to succeed the derivatives it used to offer on India’s benchmark Nifty 50. See: SGX shares opens near 7% lower on Nifty futures exit news See: Singapore turns India's Nifty in....
Read More >>

Former Malaysian PM Najib questioned by anti-graft agency

PUTRAJAYA (May 22): Former Malaysian Prime Minister Najib Razak was being questioned Tuesday by anti-corruption police about a graft scandal that could lead to criminal charges against him. He was summoned nearly two weeks after the defeat of his long-ruling coalition in national elections, a loss partly due to public anger over alleged corruption at the 1Malaysia Development Berhad (1MDB), the state investment fund that Najib set up. US investigators say Najib's associates stole and laundered US$4.5 billion ($6 billion) from the fund, some of which landed in Najib's bank account. Swa....
Read More >>

China likely to ease up slightly on financial tightening amid credit slowdown: Oxford Economics

SINGAPORE (May 22): China is likely to shift away from tighter financial policies amid a stronger-than-expected credit slowdown since December last year, even as GDP growth remains a key policy objective, according to research firm Oxford Economics. “The government has put ‘boosting domestic demand’ back on the policy agenda while de-emphasising the task of ‘deleveraging’, fuelling speculation that China is shifting away from tighter financial policies,” says lead economist Tianjie He in a report on Tuesday. However, He highlights that policymakers are not expected to make dr....
Read More >>